We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo
Read MoreHide Full Article
Exelixis, Inc. (EXEL - Free Report) announced that its partner Ipsen clinched an approval from the European Commission (EC) for the combination of the lead drug of the former, Cabomteyx (cabozantinib), and Bristol Myers’ (BMY - Free Report) immuno-oncology drug Opdivo as a first-line treatment for advanced renal cell carcinoma (RCC).
The EC nod was based on impressive results of the phase III CheckMate -9ER pivotal study wherein the combination regimen doubled progression-free survival (PFS) and the objective response rate (ORR) while significantly improving overall survival (OS) from Pfizer’s (PFE - Free Report) Sutent, which is commonly used for RCC. The combination regimen was generally well tolerated.
We remind investors that Cabometyx is already approved in the European Union as a monotherapy for the treatment of advanced RCC in adults who already received prior VEGF-targeted therapy for previously untreated intermediate- or poor-risk advanced RCC and for addressing hepatocellular carcinoma (HCC) in adults who were previously treated with sorafenib.
In January 2021, the FDA approved Cabomteyx in combination with Opdivo for the first-line treatment of advanced RCC.
Shares of the company have increased 38.2% in the past year compared with the industry’s growth of 15.7%.
Per estimates, approximately 32,000 patients in the United States and 71,000 patients worldwide will require a systemic treatment for advanced kidney cancer in 2021.
The approval of the combination regimen should give a significant boost to sales given its market potential.
The advanced RCC treatment landscape evolved in recent times and the focus shifted to immunotherapy-VEGF TKI combinations in earlier-line treatment. Most of these combinations showed immense promise. Given their market potential, most pharma/biotech bigwigs are scurrying to grab a larger chunk of this pie.
Merck’s (MRK - Free Report) immuno-oncology drug Keytruda in combination with Inlyta is also approved for the first-line treatment of patients with advanced RCC.
Meanwhile, Exelixis is currently evaluating cabozantinib for additional indications as well. Revenues generated from the drug's approved indications are expected to support its pipeline progress.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Bigstock
Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo
Exelixis, Inc. (EXEL - Free Report) announced that its partner Ipsen clinched an approval from the European Commission (EC) for the combination of the lead drug of the former, Cabomteyx (cabozantinib), and Bristol Myers’ (BMY - Free Report) immuno-oncology drug Opdivo as a first-line treatment for advanced renal cell carcinoma (RCC).
The EC nod was based on impressive results of the phase III CheckMate -9ER pivotal study wherein the combination regimen doubled progression-free survival (PFS) and the objective response rate (ORR) while significantly improving overall survival (OS) from Pfizer’s (PFE - Free Report) Sutent, which is commonly used for RCC. The combination regimen was generally well tolerated.
We remind investors that Cabometyx is already approved in the European Union as a monotherapy for the treatment of advanced RCC in adults who already received prior VEGF-targeted therapy for previously untreated intermediate- or poor-risk advanced RCC and for addressing hepatocellular carcinoma (HCC) in adults who were previously treated with sorafenib.
In January 2021, the FDA approved Cabomteyx in combination with Opdivo for the first-line treatment of advanced RCC.
Shares of the company have increased 38.2% in the past year compared with the industry’s growth of 15.7%.
The approval of the combination regimen should give a significant boost to sales given its market potential.
The advanced RCC treatment landscape evolved in recent times and the focus shifted to immunotherapy-VEGF TKI combinations in earlier-line treatment. Most of these combinations showed immense promise. Given their market potential, most pharma/biotech bigwigs are scurrying to grab a larger chunk of this pie.
Merck’s (MRK - Free Report) immuno-oncology drug Keytruda in combination with Inlyta is also approved for the first-line treatment of patients with advanced RCC.
Meanwhile, Exelixis is currently evaluating cabozantinib for additional indications as well. Revenues generated from the drug's approved indications are expected to support its pipeline progress.
Exelixis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>